COMPASS Pathways(CMPS) - 2023 Q4 - Annual Results

• Publication of results of COMP360 treatment in bipolar II depression published in JAMA Psychiatry showing a significant number of patients experience relief from their bipolar II depression symptoms after a single 25mg dose of COMP360 psilocybin treatment. 2 • Long term debt was $28.8 million as of December 31, 2023, compared with$0 million as of December 31, 2022 • Additional $31.4 million net cash raised to date in first quarter 2024 | --- | --- | --- | --- | --- | --- | --- | --- | --- | |------------ ...